Introduction
Mortality profiles show that, in most cases, after the onset of acute myocardial infarction there is too little time for successful intervention and secondary prevention. Therefore, special emphasis on primary prevention of coronary heart disease (CHD) is indicated.
CHD generally results from atherosclerosis of the coronary arteries. There is now general agreement on the view that type and amount of dietary fat can influence the genesis and course of experimental atherosclerosis (Gottenbos and Thomasson, 1961; Vies et al., 1964; Malmros, 1969) . Since atherosclerosis is a multifactorial disease (Wolf, 1971) these fat effects can be mediated by different pathways. Arterial thrombosis is the main lethal complication of atherosclerosis (Owren, 1964; Harland and Holburn, 1966; Haerem, 1974; Sinapius, 1972 Moreover, it has been shown that mural arterial thrombi become incorporated into the arterial wall (Duguid, 1946;  Sumiyoshi, More and Weigensberg, 1973; Moore, 1974) , thereby contributing to the development of the atherosclerotic plaque. Role result of vascular damage, blood inside the vessel is no longer protected from contact with subendothelial structures. This subendothelium is highly 'attractive' for blood platelets, which readily adhere to it and, thereby, become activated to produce and release substances that cause passing platelets to aggregate with the adhered ones. The newly aggregated platelets become activated as well and initiate a self-propagating process of aggregation and activation. These platelet reactions lead to the formation of a fragile platelet mass, the so-called white thrombus (Mustard and Packham, 1970 (Hornstra and Hemker, 1979 There are 2 other ways in which blood platelets participate in atherogenesis (Fig. 2) . Upon their activation they also release a so-called mitogenic factor that stimulates the proliferation of medial smooth muscle cells (Ross et al., 1974) , and their migration into the mural thrombus. These processes are considered of key importance in the formation of advanced atherosclerotic lesions (Ross and Glomset, 1976) . Moreover, activated platelets release serotonin, which induces endothelial contraction and facilitates lipid infiltration into the arterial wall as well as thrombus formation (Shimamoto, 1974) . In experimental animals, a key role of platelets in atherogenesis has been demonstrated very convincingly (Harker et al., 1976; Moore et al., 1976; Friedman et al., 1977; Fuster and Bowie, 1978) (Hornstra and Lussenburg, 1975) .
Human studies
Although these experimental results have been confirmed by many other investigators using a great variety of animal models (Renaud and Gautheron, 1973/74; Hornstra, 1973/74) (Stamler, 1973; Heyden, 1975 (Leren, 1966; Dayton et al., 1969;  Miettinen et al. (1972) ). The beneficial effects of these diets are not necessarily the result of their plasma lipid-lowering action only, but may be mediated by their effect on platelet thrombotic functions as well.
In this respect, recent results of Renaud et al. (1979) are of extreme interest. They selected 2 regions in France and 2 in Scotland with marked differences in mortality from CHD. Here they surveyed the diet, determined the classical risk factors (blood lipids, blood pressure, smoking habits, etc.) and, moreover, performed tests for platelet reactivity. It then appeared that there were no differences in blood lipid levels between the high-and low-risk regions, although the saturated fat intake differed significantly. Blood platelets, on the other hand, appeared to be hyperactive in the high risk group, especially as far as their participation in blood clotting and aggregation in response to thrombin is concerned. In fact, these platelet functions appeared to be the only blood parameters related to the incidence of CHD in these regions.
A contribution of thrombotic platelet functions to mortality from CHD is also suggested from aggregation studies performed at the end of the Helsinki primary prevention trial (Miettinen et al., 1972) . This study was conducted in 2 mental hospitals (K and N). In the control hospital (N) the normal Finnish diet, which is rich in saturated fats and contains only 4% of its digestible energy as linoleic acid, was given all the time. In the other hospital (K), the diet was modified: milk was replaced by soy-bean oil-filled skim milk whereas butter and ordinary margarines were replaced by so-called 'soft' margarines, resulting in a dietary linoleic acid content of 12% energy. After 6 years the diets were reversed, the total experimental period being 12 years. Then it appeared that in men, but not in women, the high linoleic acid diet was associated with a 50% reduction in mortality from CHD. At the end of the second 6-year period the opportunity occurred to measure the platelet aggregation which, in the rat studies, had been shown to correlate well with the arterial thrombosis tendency (Hornstra and Lussenburg, 1975) . Measurements were carried out with a newly developed device, the filtragometer (Hornstra and ten Hoor, 1975) . Blood from a forearm vein is drawn through a microfilter at a constant rate of 2 ml/min. Blood pressures are measured at both sides of the filter, and the difference (AP) is recorded continuously. The blood is anticoagulated with heparin. When platelets present in the blood aggregate and obstruct the filter, the pressure difference across the filter changes. This is indicated by a rise in the AP-curve. At a AP-value of 5 mmHg, heparin is replaced by sodium citrate. This lowers the free calcium content of the blood and so results in dispersion of the aggregation on the filter. Consequently, AP decreases again. From the AP-curve the various aggregation and de-aggregation parameters are calculated. The filtragometer proved to be a suitable device for monitoring the anti-platelet effects of oral aspirin and of prostaglandin El. Moreover, it appeared that women have a lower platelet aggregation than men. (Hornstra, 1978) . As is shown in Fig. 3 , the filtragometer response is definitely lower in the high linoleic acid group than in the control group. Since mortality from CHD is often associated with occlusive coronary thrombosis-in which platelet aggregation is involved-it is highly probable that the low platelet aggregation in the high linoleic acid group, contributed to the lower mortality . As stated before, the Helsinki primary prevention trial was carried out in 2 different hospitals using a cross-over design. During the second 6-year period, hospital K was given the experimental diet whereas in hospital N the normal control diet was provided. After the end of this second period the first aggregation measurements were performed showing a decreased platelet aggregation in the experimental group. Nine months later, the experimental diet was replaced by the normal diet. In the meantime, however, new patients had entered hospital K who, at the moment of the dietary change, had been on the experimental diet for only a relatively short period. Three months after return to the normal diet in hospital K, platelet aggregation was re-studied in both hospitals. Results are given in Table 1 . Owing to a technical modification of the filtragometer device the aggregation values obtained at the second measurement were different from the first values. However, in the control hospital no dietary change had occurred so at both measurements platelet aggregation can be taken as 100%. In those subjects from hospital K who had been in the trial all the time, the dietary change caused an increase in platelet aggregation to a level rather close to, but still significantly lower than that in hospital N. In those subjects who had been offered the high linoleic acid diet for less than 9 months before they changed to the normal diet, platelet aggregation was not different from that in the control group. This finding strongly suggests that linoleic acid in adipose tissue, which has a much slower turn-over than that in blood lipids (Dayton, 1966; Fleischman, Hayton and Bierenbaum, 1967) , in some way has a long-term protective effect after pro-thrombotic dietary changes. The same suggestion was obtained from animal experiments since the arterial thrombosis tendency in rats fed a thrombogenic diet increased more slowly, the longer the animals had been pre-treated with an antithrombotic diet rich in linoleic acid (Hornstra, 1975 (Oliver, Kurien and Greenwood, 1968; Kurien and Oliver, 1970 (Vogt, 1978) , but especially since the vast amount of data indicating the beneficial effect of such a diet will prevent this trial from being accepted by any ethical committee.
Another convincing approach might therefore be to unravel the mechanisms by which the dietary fat type affects atherosclerosis, arterial thrombosis and-ultimately-platelet thrombotic functions. Apart from the composition of adipose tissue and plasma FFAs, discussed above, the thromboxane/ prostacyclin balance, platelet membrane fluidity and the coagulation response following blood-vessel wall interaction may be of importance in this respect.
The tendency to arterial thrombosis is now thought to depend on the ratio between prothrombotic thromboxane A2 (TxA2) produced by activated blood platelets and antithrombotic prostaglandin I2 (prostacyclin, PGI2) formed in vascular tissue . Both substances have the same precursor fatty acid, arachidonic acid, which is mainly synthesized in the body from dietary linoleic acid. Therefore, it is tempting to speculate that the anti-thrombotic effect of oils rich in linoleic acid is mediated by a change of this thromboxaneprostacyclin balance towards a less thrombogenic state. However, this appeared not to be so: although a high linoleic acid diet increases the obstruction time in rats significantly as compared to a low linoleic acid or a high saturated fat diet (and consequently lowers the tendency to arterial thrombosis), production of platelet TxA2 (measured as its metabolite malondialdehyde) and of vascular prostacyclin is hardly affected.
However, the thromboxane-prostacyclin concept might be an oversimplification of the thromboregulatory mechanism because other prostaglandins are formed as well, some of which (PGEi, PGD2) have distinct anti-aggregation effects on blood platelets (Kloeze, 1967; Smith, Silver and Ingerman, 1974) . This might be the more important since feeding increasing amounts of linoleic acid to rat and man causes the urinary excretion of prostaglandin E and F metabolites to increase proportionally (Z6llner, Adam and Wolfram, 1979; Nugteren et al., 1980) . Moreover, replacement of dietary saturated fatty acids by linoleic acid has been shown to result in an increased prostaglandin production of stimulated rat adipocytes (Lipinski and Mathias, 1978) , and of an enhanced prostaglandin synthetic potential of rat whole lung (Meydani, Mathias and Schatte, 1978) .
Platelet plasma membranes-like all other mammalian plasma membranes-are mainly composed of a phospholipid bilayer, free cholesterol and proteins (Singer and Nicolson, 1972) . These membranes have a certain fluidity which is essential for their function (Sinha, Shattil and Colman, 1977) . A major determinant of membrane fluidity is the molar ratio between the membrane-free cholesterol and phospholipid content (C/P ratio) (Vanderkooi et al., 1974; Shattil and Cooper, 1976; Demel and de Kruijff 1976) . Following an increase in their C/P ratio in vitro (causing an enhanced membrane fluidity) the aggregation tendency of platelets increases (Shattil et al., 1975) , as does platelet thromboxane production in response to thrombin (Stuart, Gerrard and White, 1980) . This indicates that membrane fluidity may affect platelet function. Indeed, platelets of patients suffering from type IIa hyperlipoproteinaemia showed an increased C/P ratio and were hypersensitive towards activation (Carvalho, Colman and Lees, 1974; Shattil et al., 1977; Tremoli et al., 1979a, b) . In rats, the dietary fat type may be able to modify platelet C/P ratio (Hornstra, 1975) . Moreover, it determines platelet phospholipid fatty acid composition (Renaud et al., 1970; Nordoy and Rodset, 1971; Hornstra, 1975) which is also implicated in membrane fluidity (Shinitzky and Barenholz, 1978) . Therefore, the type of dietary fat might be able to modify platelet membrane fluidity. Recently, preliminary results have been reported which confirm this suggestion (Berlin and Young, 1979) but further experiments are needed to demonstrate that this mechanism is involved in dietary fat-induced changes in platelet function and thrombosis.
Injured vascular tissue has thromboplastic activity, as a result of which vascular damage triggers blood clotting. Thrombin generated as a result of this clotting response is of key importance in platelet aggregation following vascular injury (Hornstra and Hemker, 1979 (Walsh, 1974; Hornstra and Hemker, 1979) . In extensive series of experiments it has been shown that the type of dietary fat greatly influences platelet clot-promoting activity in rats and rabbits Gautheron, 1973/74, 1975; Tremoli, 1977) . In humans, an increased risk for coronary thrombosis coincides with an enhanced clot-promoting effect of the platelets (Renaud et al., 1979) . This platelet hyper-reactivity was shown to return to normal simply by replacing butter, cream and milk with 'soft' margarines, vegetable oils and low fat milk. These findings may present an explanation for the effect of linoleic acid-rich oils in lowering the tendency to thrombosis.
Fish oils and arterial thrombosis
Based on epidemiological studies in Greenland Eskimoes, Dyerberg and his colleagues advocated dietary enrichment with PFAs present in fish oils, especially with eicosapentaenoic acid (EPA). This fatty acid is the precursor of the 3-series prostaglandins of which platelet TxA3 has only weak prothrombotic properties; whereas PGI3, possibly produced in the vascular wall, is an antithrombotic substance as active as prostacyclin. Therefore, these workers suggested that, apart from its blood lipid-lowering effect, EPA might retard the development of atherosclerosis by changing the thromboxane-prostacyclin balance towards a less thrombogenic state (Dyerberg et al., 1978; Dyerberg and Bang, 1979) .
The present author indeed confirmed the antithrombotic effect of cod liver oil in rats, which appeared to coincide with a highly reduced production of platelet thromboxanes. However, vascular prostacyclin formation was reduced to the same extent, whereas PGI3 was not formed in measurable amounts. These findings could be explained on the basis of the fatty acid spectra of platelet and vessel wall phospholipids as well as by the fact that EPA is a poor substrate for prostaglandin-producing enzymes (Hornstra, Haddeman and ten Hoor, 1979) . It should be noted that not all marine oils have the same anti-thrombotic potency as cod liver oil. Whale oil, for instance, is slightly thrombogenic (Hornstra and Lussenburg, 1975) (Gudbjarnason and Hallgrimsson, 1976; Gudbjarnason, 1980) . Moreover, a relatively large intake of fish oils is held responsible for yellow fat disease, a generalized disorder of fatty depots observed in a wide variety of animal species (Ruiter et al., 1978) . Therefore, it seems premature to advocate a general dietary use of these oils.
Concluding remarks
After the onset of myocardial infarction about 50 % of patients die within a few hours, leaving too little time for successful intervention and/or secondary prevention. This implies that primary prevention of coronary disease is of major importance. CHD results from atherosclerosis of the coronary arteries. Blood platelets have been shown to contribute to genesis, course and complications of the atherosclerotic process. Therefore, lowering enhanced platelet reactivity should be one of the objectives of primary prevention. One of the possibilities of achieving this goal is to change the dietary composition. Based on experimental studies in animals and man, partly discussed here, a decreased intake of saturated fatty acids is recommended together with an increased consumption of polyunsaturated fatty acids, especially of the linoleic acid family. In practice, this means an enhanced intake of linoleic acid-rich products. This would not only lower the tendency to arterial thrombosis, but other atherosclerosis risk factors as well, since linoleic acid has been shown to decrease serum cholesterol, especially LDL cholesterol, to lower 'borderline' hypertension and to normalize biochemical abnormalities in obesity and maturity onset diabetes. Moreover, animal studies clearly indicate that a linoleic acid-rich diet improves cardiac perfusion and work capacity (Vergroesen et al., 1980) . Finally, no major adverse effect of dietary linoleic acid has ever been reported which, on careful screening of the data, could not be dismissed (Heyden, 1975 
